Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Extended followup indicates daratumumab with bortezomib and dexamethasone for...

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Enasidenib in mIDH relapsed and refractory AML

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

$Enasidenib in mIDH relapsed and refractory AML ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )$

Impact of mutational profile at diagnosis for MDS/CML

Dr Guillermo Montalban Bravo - MD Anderson Cancer Center, Houston, USA

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany

Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

The role of patient advocates in trial design, participation

Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy

The role of patient advocates in trial design, participation ( Sarah Liptrott - Eurpean Institute of Oncology, Milan, Italy )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

Phase Ib/II study of nivolumab in combination with azacytidine in patients with...

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid...

Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Dr Max Topp - University of Wurzburg, Wurzburg, Germany

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )

Blood thinners a risk with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...

Blood thinners a risk with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL

Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL ( Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA )

More from ecancer